

Mr-Proadrenomedullin As Biomarker Of Renal Damage In Urinary Tract Infection In Children

Rafael Peñalver Penedo (✉ penalver.rafa@gmail.com)

CA Soria: Complejo Asistencial de Soria <https://orcid.org/0000-0002-7594-225X>

Marta Rupérez Lucas

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

Luis Antonio Álvarez-Sala Welther

Gregorio Maranon Health Research Institute: Instituto de Investigacion Sanitaria Gregorio Maranon

Alicia Torregrosa Benavent

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

María Luisa Casas Losada

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

Luis Bañuelos Andrio

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

Ana Belén Rebolledo Poves

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

María Mercedes Bueno Campaña

Alcorcon Hospital Foundation: Hospital Universitario Fundacion Alcorcon

Research article

Keywords: Proadrenomedullin, biomarker, urinary tract infection, pediatric, renal scarring

Posted Date: March 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-279445/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

TITLE:

MR-PROADRENOMEDULLIN AS BIOMARKER OF RENAL DAMAGE IN URINARY TRACT INFECTION IN CHILDREN

AUTHORS:

- Corresponding Author: Peñalver Penedo, Rafael (Servicio de Pediatría, Hospital Santa Bárbara, Soria. Departamento de Medicina. Facultad de Medicina. Universidad Complutense de Madrid, Spain) – rpenalver@saludcastillayleon.es - ORCID: 0000-0002-7594-225X
- Rupérez Lucas, Marta (Servicio de Pediatría, Hospital Universitario Fundación Alcorcón, Madrid, Spain) – ORCID: 0000-0003-3881-0941
- Álvarez-Sala Walther, Luis Antonio (Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón. IiSGM. Instituto de Investigaciones Sanitarias Gregorio Marañón. Departamento de Medicina. Facultad de Medicina. Universidad Complutense de Madrid, Spain) – ORCID: 0000-0003-1781-5364
- Torregrosa Benavent, Alicia (Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón, Madrid, Spain)
- Casas Losada, María Luisa (Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón, Madrid, Spain)
- Bañuelos Andrio, Luis (Servicio de Medicina Nuclear, Hospital Universitario Fundación Alcorcón, Madrid, Spain)
- Rebolledo Poves, Ana Belén (Biobanco, Hospital Universitario Fundación Alcorcón, Madrid) – ORCID: 0000-0002-3151-7999
- Bueno Campaña, Mercedes (Servicio de Pediatría, Hospital Universitario Fundación Alcorcón, Madrid, Spain) – ORCID: 0000-0001-6732-733X

ABSTRACT**Background:**

Midregional-proadrenomedullin (MR-proADM) is a useful prognostic peptide in severe infectious pathologies in the adult population. However, there are no studies that analyze its utility in febrile urinary tract infection (fUTI) in children. An accurate biomarker would provide an early detection of patients with kidney damage, avoiding other invasive tests like renal scintigraphy scans. Our objective is to study the usefulness of MR-proADM as a biomarker of acute and chronic renal parenchymal damage in fUTI within the pediatric population.

Methods:

A prospective cohort study was conducted in pediatric patients with fUTI between

January 2015 and December 2018. Plasma and urine MR-proADM levels were measured at admission in addition to other laboratory parameters. After confirmation of fUTI, renal scintigraphy scans were performed during the acute and chronic stages. A descriptive study has been carried out and sensitivity, specificity and ROC curves for MR-proADM, C-reactive protein, and procalcitonin were calculated.

Results:

62 pediatric patients (34 women) were enrolled. Scintigraphy showed acute pyelonephritis in 35 patients (56.5%). Of those patients, median of plasmatic MR-proADM (P-MR-proADM) showed no differences compared to patients without pyelonephritis. 7 patients (11.3%) developed renal scars (RS). Their median P-MR-proADM levels were 1.07 nmol/L (IQR 0.66 – 1.59), while in patients without RS were 0.48 nmol/L (0.43 – 0.63) ($p < 0.01$). The AUC in this case was 0.92 (95% CI 0.77 – 0.99). We established an optimal cut-off point at 0.66 nmol/L with sensitivity 83.3% and specificity 81.8%.

Conclusion:

MR-ProADM has a poor ability to diagnose pyelonephritis in pediatric patients with fUTI. However, P-MR-proADM showed as a very reliable biomarker for RS prediction.

Abbreviations:

ADM: Adrenomedullin, APN: Acute Pyelonephritis, AUC: Area Under Curve, CRP: C-reactive protein, DMSA: ^{99m}Tc dimercaptosuccinic acid scintigraphy, eGFR: estimated glomerular filtration rate, FENa: Fractional Excretion of Sodium, FE MRproADM: Fractional Excretion of MR-proADM, fUTI: febrile Urinary Tract Infection, IQR: Interquartile Range, MR-proADM: Mid-regional proadrenomedullin, NPV: negative

predictive value, PCT: procalcitonine, P-MR-proADM: Plasmatic midregional-proadrenomedullin, PPV: positive predictive value, RS: renal scarring, Se: sensitivity, Sp: specificity, U-MR-proADM: urinary midregional-proadrenomedullin, UCr: urinary creatinine, US: ultrasonography, ROC Curve: Receiving Operating Characteristic curve.

Keywords: Proadrenomedullin, biomarker, urinary tract infection, pediatric, renal scarring

INTRODUCTION:

Urinary tract infection is one of the most common infectious pathologies in infant age [1]. Although most have excellent prognosis, when there is renal parenchymal involvement, defined as acute pyelonephritis (APN), it leads to increased associated morbidity. In up to 15% of these patients, parenchymal damage can be permanently established, known as RS [2, 3] which may lead to developing proteinuria, high blood pressure and chronic renal failure in the future [4, 5].

Among the known risk factors for RS, the most relevant include the presence of vesicoureteral reflux, bladder dysfunction, previous nephropathies or APN, the type of pathogen, the time of symptom evolution, fever greater than 39°C, as well as a delayed initiation of the antibiotic treatment [6, 7].

Renal cortical scintigraphy with ^{99m}Tc dimercaptosuccinic acid (DMSA scan) is the gold standard for the diagnosis of APN and RS [8, 9]. However, it is an invasive test, which radiates the patient and is not available in all centers. On the other hand, there are biomarkers of parenchymal involvement like C-reactive protein (CRP) or procalcitonin (PCT), but none of them are sensitive and specific enough to replace DMSA scan [10–13]. For this reason, new molecules that can help with an early detection of those patients at risk of kidney damage continue to be investigated [14, 15].

Adrenomedullin (ADM) is a vasoactive peptide isolated in 1993 with ubiquitous tissue distribution and gene expression. It works as an autocrine and paracrine hormone, and it is also found as a circulating hormone, free or bound to the complement factor H. Its plasmatic levels are increased in various infectious, cardiovascular and renal impairment

pathologies [16–18].

Due to its instability, determination of ADM is not appropriate for diagnostic assessment in routine clinical care. However, the MR-proADM has been identified as a stable and reliable indirect marker of ADM release, with equivalent plasmatic levels [19].

There are studies that has demonstrated the usefulness of MR-proADM as a prognostic biomarker in severe infectious pathologies in the adult population, such as sepsis, fUTI or severe community-acquired pneumonia [20–24]. However, studies analyzing their usefulness as a marker for severe infections in childhood are rare, while there are no such studies for fUTI [25–27].

The main objective of this study is to explore the diagnostic ability of MR-proADM in the APN in pediatric population with fUTI and its possible prognostic value as a predictor of RS development, using DMSA scan as a reference test.

Secondary objectives are to compare the diagnostic accuracy of MR-proADM in fUTI with CRP and PCT using ROC curves, to combine biomarkers to improve their diagnostic ability, and to correlate MR-proADM levels with glomerular filtration rate and tubular function.

MATERIAL AND METHODS:

A prospective cohort study was developed in the Pediatrics Unit of the Fundación de Alcorcón University Hospital, second-level hospital of the Comunidad de Madrid (Spain). The study period covered from January 2015 to December 2018 and obtained the

hospital's Research and Ethics Committee approval on 18 July 2013. Considering our hospital previous admissions of patients with fUTI, the estimates per year were of 45 patients.

Those pediatric patients diagnosed in the Emergency Room with suspected fUTI that met the inclusion criteria (table 1) were included, upon permission of the children's parents or legal guardians through informed consent.

According to the center's protocol, patients' history and epidemiological data were collected at admission. An analytical study was conducted, urine culture was ordered and empirical antibiotic therapy was started. Blood count and plasma concentration of creatinine, electrolytes, CRP and PCT were measured. Urine dipsticks (Aution Sticks®, Arkray Europe) were used to determine nitrites, proteinuria, leukocyturia and hematuria (semi-quantitative results). To assess tubular function, urinary creatinine and electrolytes were measured and fractional excretion of sodium (FENa) was calculated. Glomerular filtration rate was estimated (eGFR) and adjusted using 2009 Schwartz formula [28, 29]. Samples of MR-proADM were collected in plasma and urine (P-MR-proADM and U-MR-proADM, respectively). They were centrifuged and stored at -80°C in the center's biobank to be analyzed altogether in the last stage of the study.

After positive urine culture confirmed fUTI, nephro-urological ultrasound and DMSA scan were made to all patients during acute stage in order to detect possible malformations and renal parenchymal damage. 2-4 mCi of DMSA were injected intravenously, obtaining static images in posterior and oblique projection in gamma camera, at least 2 hours after injection. APN and RS were defined as the presence of focal or diffuse areas of decreased

isotope uptake. After hospital discharge, all patients were followed up. Since the absence of acute parenchymal damage allows to assume the absence of RS development [3], chronic DMSA scans were only made in patients diagnosed of APN, and at least 9 months after the acute infection.

At the last stage of the study, stored MR-proADM samples from all patients enrolled were analyzed. The determination was made in EDTA plasma by sandwich-type fluorescence immunoassay (MR-proADM, Thermo Fisher Scientific-BRAHMS GmbH, Hennigsdorf, Germany). The quantification limit has been evaluated as 0.23 nmol/L [30].

There are currently no P-MR-proADM reference values established in pediatric population, only in cord blood [31] and newborns [32]. Therefore, the cut-off value for P-MR-proADM of 0.55 nmol/L as p97.5 of normal was used, as it was established in the Caruhel's et al. study referred in the manufacturer insert [33].

Although, as the manufacturer indicates, the test has not been validated to be used with urinary samples, we decided to test also MR-proADM in urine under the same conditions as in plasma samples. Also, normal values of U-MR-proADM have not been published in the literature. For proper analysis and to be able to establish appropriate comparisons, different urinary indexes were also established: U-MR-proADM / P-MR-proADM, U-MR-proADM / urinary creatinine, fractional excretion of MR-proADM (FE_{proADM}).

Data analysis was performed using statistical packages SPSS 17 and STATA 14.

Quantitative variables were presented as median and interquartile range (IQR, p25-p75) and categorical data were expressed as absolute values and percentages. Univariate

analysis was performed to compare both groups, that with and that without APN: Chi-squared test or Fisher test in case of categorical variable and non-parametric U Mann Whitney test in case of quantitative data. To evaluate the predictive accuracy of biochemical parameters, area under ROC curve (AUC) was estimated and binomial exact 95% confidence interval was calculated. The validity index of sensitivity (Se) and specificity (Sp) and the utility index of positive (PPV) and negative predictive value (NPV) were estimated with 95% confidence interval for reported cut-off values. The same methods were used to analyze the predictive accuracy of biochemical parameters in RS diagnosis. P-values < 0.05 were considered statistically significant.

RESULTS

Samples were collected from 62 patients (34 women), with a median age of 7 months (IQR 2.5 – 11.3). E.coli was isolated in 57 (91.7%) urine cultures. Table 2 lists epidemiological, clinical and analytical data (including different biomarkers) of the total sample and subgroups with APN and RS.

35 patients (56.5%) were diagnosed with APN after DMSA scan in the acute stage. Among them, 7 patients with APN (22.6%) showed RS in scans performed at the chronic stage.

We found that the median P-MR-proADM in patients with and without APN was 0.59 nmol/L (IQR 0.45 – 0.72) and 0.63 nmol/L (0.53 – 0.83) (p=0.25), respectively. In urine, the median values of U-MR-proADM in patients with APN were 0.56 nmol/L (IQR 0.19 – 0.82), while in patients without acute parenchymal damage were 0.23 nmol/L (0.14 – 0.50) (p=0.044). We found no significant differences when analyzing the different urinary

indexes (table 2).

Figure 1 shows the ROC curves and the AUC of the different biomarkers in the acute phase. For P-MR-proADM, U-MR-proADM, CRP and PCT the AUC was 0.41 (95% CI 0.28 – 0.55), 0.67 (95% CI 0.51 – 0.79), 0.81 (95% CI 0.70 – 0.91) and 0.74 (95% CI 0.55 – 0.86), respectively. For the normal cut-off point of 0.55 nmol/L, P-MR-proADM had Se 53%, Sp 31.8%, PPV 53% and NPV 31.8%. We have not found an optimal cut-off point that improves the validity of this test. The combination of MR-proADM with other biomarkers also did not improve either the Se or Sp.

In the follow-up, DMSA scan was made in 31 of the patients with APN at the chronic stage. When studying patients with RS, the median P-MR-proADM at admission was 1.07 nmol/L (IQR 0.66 – 1.59), compared to 0.48 nmol/L (IQR 0.43 – 0.63) in those with normal scan ($p < 0.002$).

Figure 2 shows the ROC curves and AUC of the biomarkers analyzed in patients in the chronic phase. The P-MR-proADM, CRP and PCT AUC in this case were 0.92 (95% CI 0.77 – 0.99), 0.87 (95% CI 0.70 – 0.96) and 0.92 (95% CI 0.70 – 1), respectively. For the normal cut-off point of 0.55 nmol/L, P-MR-proADM has PPV 20%, NPV 100%, 100% and Sp 47.8%. Setting 0.66 nmol/L as an optimal cut-off point, we obtain a Se of 83.3% and Sp of 81.8%.

With regard to U-MR-proADM, although in patients with RS the medians of both absolute values and different urinary indices were higher than in patients with normal DMSA scans, in none of the cases these differences were significant (Table 2). None of

the RS patients had a normal eGFR.

We observed that P-MR-proADM with eGFR and FENa had a Spearman correlation coefficient of -0.120 (p=0.38) and -0.229 (p=0.01), respectively. In the case of U-MR-proADM, the correlation coefficient was -0.02 (p=0.9) with the eGFR and -0.1 (p=0.5) with FENa.

None of the patients developed severe complications such as sepsis or bacteremia. After collecting the urine culture results the antibiotic therapy was adjusted, fever disappeared in less than 72 hours and complete recovery of the acute process was achieved in all cases. At the time of this study, none of the patients followed up has developed any complications.

DISCUSSION

The main findings of our study are the poor ability of P-MR-proADM to diagnose APN in pediatric patients with fUTI, and its excellent prognostic capacity to predict RS development.

We have found significantly higher levels of P-MR-proADM in patients who subsequently developed RS. Furthermore, none of the patients who had normal levels (<0.55 nmol/L) of P-MR-proADM at the time of diagnosis did develop RS in the follow-up.

These findings show that a baseline level of P-MR-proADM at the time of diagnosis can

provide the physician valuable information on the possible severe evolution and prognosis of some patients, avoiding thorough monitoring and control scans to those with normal figures at admission.

The fact that the gene expression of ADM is stimulated by endotoxins and bacterial cytokines, and that it is a protein binding to complement Factor H, allows us to assume that the ADM has an antibacterial role and inflammation mediator [18, 34, 35]. In the case of APN, kidney damage and subsequent evolution to RS are known to be due to inflammation caused by primary immunity (complement) in its attack on the pathogen [36], but all the local factors involved have not been clarified yet. We hypothesize that, if acute parenchymal damage is very important, a large amount of ADM is released locally, joining a part to the complement Factor H, thus, inactivating it and allowing the alternative route of complement to act and "to damage" the parenchyma. This would happen more intensely in those APN with a significant increase in ADM production and subsequently evolving to RS.

Although urinary MR-proADM is increased in both APN and RS patients, which would be in line with Kalman's studies with ADM [34, 37], the different urinary rates proposed do not show significant differences. It has been documented that an impaired renal function involves an elevation of MR-proADM plasma levels, suggesting glomerular filtration of the molecule [38]. In our sample, patients with APN and RS had transiently decreased eGFR compared with patients without parenchymal damage, which could affect glomerular excretion of the molecule.

To our knowledge, this is the first prospective study focusing on the diagnostic and

prognostic value of MR-proADM in children with fUTI, and making a comparison to currently available biomarkers like PCT and CRP.

One of the main limitations of the study is sample size, as the study design was estimated for 45 patients per year. Factors that reduced the estimated sample size include: reduction of the number of emergencies at the center, refusal of the parents to sign the informed consent, loss of biobank samples by incorrect labeling at the beginning of the study, loss of patients during the follow-up. In addition, in 2017 there was a change in the fUTI protocol at our center, limiting the indications for DMSA scan, thus, we had a decreasing number of patients to carry out a complete study.

In conclusion, in our sample neither plasma nor urinary MR-ProADM has proved a better capacity than CRP or PCT to diagnose acute parenchymal damage in pediatric patients diagnosed with fUTI. However, P-MR-ProADM does appear to have prognostic utility as a RS predictor, with AUC, Se and Sp similar to CRP and PCT.

We consider that MR-proADM is a peptide of great interest for the study of fUTI in the pediatric population, as it could have potential as a predictor of RS, although more studies are needed to support our results.

DECLARATIONS:

- **Funding:** The study received funding from the Research Aid Award in 2014 from the Fundación Alcorcón University Hospital, receiving for it the amount of 9405 euros to develop the study. The funder made no intervention at any step of the study.
- **Competing interests:** The authors declare that they have no conflict of interest.
- **Ethics approval:** this study obtained the Fundación de Alcorcón University Hospital's Research and Ethics approval on 18 July 2013
- **Consent to participate:** written informed consent was obtained from legal guardians.
- **Consent for publication:** legal guardians of the patients signed informed consent regarding publishing their data and photographs
- **Availability of data and material (data transparency):** All authors are requested to make sure that all data and materials as well as software application or custom code support their published claims and comply with field standards. Please note that journals may have individual policies on (sharing) research data in concordance with disciplinary norms and expectations.
- **Authors Contribution: Conceptualization and Methodology:** Rafael Peñalver Penedo, Marta Rupérez Lucas, Mercedes Bueno Campaña; **Formal analysis and investigation:** Rafael Peñalver Penedo, Marta Rupérez Lucas, Mercedes Bueno Campaña; Elia Pérez Fernández; **Writing - original draft preparation:** Rafael Peñalver Penedo; **Writing - review and editing:** Rafael Peñalver Penedo, Marta Rupérez Lucas, Mercedes Bueno Campaña; **Funding acquisition:** Marta Rupérez Lucas, Mercedes Bueno Campaña; **Supervision:** Marta Rupérez Lucas, Mercedes Bueno Campaña; Luis Antonio Álvarez-Sala Welther.

- **Acknowledgments:** To Elia Pérez Fernández, from the Research Unit of the Fundación Alcorcón University Hospital, for statistical analysis of the sample.


BIBLIOGRAPHY:

1. Shaikh N, Morone NE, Bost JE, Farrell MH. Prevalence of urinary tract infection in childhood: A meta-analysis. *Pediatr Infect Dis J*. 2008;27(4):302–8.
2. Kosmeri C, Kalaitzidis R, Siomou E. An update on renal scarring after urinary tract infection in children: what are the risk factors? *J Pediatr Urol* [Internet]. 2019;15(6):598–603. Available from: <https://doi.org/10.1016/j.jpurol.2019.09.010>
3. Shaikh N, Ewing AL, Bhatnagar S, Hoberman A. Risk of renal scarring in children with a first urinary tract infection: A systematic review. *Pediatrics*. 2010;126(6):1084–91.
4. Jacobson SH, Eklof O, Eriksson CG, Lins LE, Tidgren B, Winberg J. Development of hypertension and uraemia after pyelonephritis in childhood: 27 year follow up. *Br Med J*. 1989;299(6701):703–6.
5. Wennerström M, Hansson S, Jodal U, Sixt R, Stokland E. Renal function 16 to 26 years after the first urinary tract infection in childhood. *Arch Pediatr Adolesc Med*. 2000;154(4):339–45.
6. Oh MM, Kim JW, Park MG, Kim JJ, Yoo KH, Moon DG. The impact of therapeutic delay time on acute scintigraphic lesion and ultimate scar formation in children with first febrile UTI. *Eur J Pediatr*. 2012;171(3):565–70.
7. Shaikh, Nader; Hoberman A. Urinary tract infections in children: Epidemiology and risk factors. In: *UpToDate* [Internet]. Wolters Kluwer; 2020. p. 1–3. Available from: <https://www.uptodate.com/contents/urinary-tract-infections-in-children-epidemiology-and-risk-factors>
8. Goldraich NP, Goldraich IH, Unit PN, Nefrologia C De, Porto I. Pediatric Nephrology Practical pediatric nephrology Update on dimereaptosueenie acid renal scanning in children with urinary tract infection. *Pediatr Nephrol*. 1995;221–6.
9. Piepsz A, Blaufox MD, Gordon I, Granerus G, Majd M, O'Reilly R, et al. Consensus on renal cortical scintigraphy in children with urinary tract infection. *Semin Nucl Med*. 1999;29(2):160–74.
10. Garin EH, Olavarria F, Araya C, Broussain M, Barrera C, Young L. Diagnostic significance of clinical and laboratory findings to localize site of urinary infection. *Pediatr Nephrol*. 2007;22(7):1002–6.
11. Fernandez- A, Nikfar R, Romanello C, Gervaix A, Metin K, Bressan S, et al. Association of Procalcitonin With Acute Pyelonephritis and Renal Scars in Pediatric UTI. *Pediatrics*. 2013;131(5):X5–X5.
12. Bañuelos-Andrío L, Espino-Hernández M, Ruperez-Lucas M, Villar-del Campo MC, Romero-Carrasco CI, Rodríguez-Caravaca G. Utilidad de los parámetros analíticos en el manejo de los pacientes pediátricos con sospecha de pielonefritis aguda. ¿Es fiable la procalcitonina? *Rev Esp Med Nucl Imagen Mol*. 2017;36(1):2–6.
13. Shaikh N, Borrell JL, Evron J, Leeflang MM. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. *Cochrane Database Syst Rev*. 2015;2017(6).
14. Lee JH, Yim HE, Yoo KH. Associations of plasma neutrophil gelatinase-associated lipocalin, anemia, and renal scarring in children with febrile urinary tract infections. *J Korean Med Sci*. 2020;35(10):1–14.
15. Kitao T, Kimata T, Yamanouchi S, Kato S, Tsuji S, Kaneko K. Urinary

- biomarkers for screening for renal scarring in children with febrile urinary tract infection: Pilot study. *J Urol* [Internet]. 2015;194(3):766–71. Available from: <http://dx.doi.org/10.1016/j.juro.2015.04.091>
16. Samson WK. Proadrenomedullin-Derived Peptides. 1998;127(19):100–27.
 17. Pío R, Martínez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, et al. Complement Factor H Is a Serum-binding Protein for Adrenomedullin, and the Resulting Complex Modulates the Bioactivities of Both Partners. *J Biol Chem*. 2001;276(15):12292–300.
 18. M.Y. Cheung B, Tang F. Adrenomedullin: Exciting New Horizons. *Recent Pat Endocr Metab Immune Drug Discov*. 2012;6(1):4–17.
 19. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. *Clin Chem*. 2005;51(10):1823–9.
 20. Cavallazzi R, El-Kersh K, Abu-Atherah E, Singh S, Loke YK, Wiemken T, et al. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: A systematic review. *Respir Med* [Internet]. 2014;108(11):1569–80. Available from: <http://dx.doi.org/10.1016/j.rmed.2014.09.018>
 21. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. *Crit Care*. 2005;9(6):816–24.
 22. Litke A, Bossart R, Regez K, Schild U, Guglielmetti M, Conca A, et al. The potential impact of biomarker-guided triage decisions for patients with urinary tract infections. *Infection*. 2013;41(4):799–809.
 23. Stalenhoef JE, Van Nieuwkoop C, Wilson DC, Van Der Starre WE, Van Der Reijden TJK, Delfos NM, et al. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection. *BMC Infect Dis*. 2019;19(1):1–10.
 24. Rey C, García-Hernández I, Concha A, Martínez-Camblor P, Botrán M, Medina A, et al. Pro-adrenomedullin, pro-endothelin-1, procalcitonin, C-reactive protein and mortality risk in critically ill children: A prospective study. *Crit Care*. 2013;17(5):1–9.
 25. Bueno Campaña M, Rupérez Lucas M, Fernández Rincon A, Calvo C, Moran Roldan L, de la Morena Martinez R. Mid-regional pro-adrenomedullin could be a biomarker of severity in bronchiolitis. *Acta Paediatr Int J Paediatr*. 2018;107(8):1467–8.
 26. Kannan R, Rao SS, Mithra P, Dhanashree B, Baliga S, Bhat KG. Diagnostic and Prognostic Validity of Proadrenomedullin among Neonates with Sepsis in Tertiary Care Hospitals of Southern India. *Int J Pediatr*. 2018;2018:1–5.
 27. Elmoutaleb ATA, Aly HA, Bayomy EM, Abdelhamed MR, Esmael NF. Plasma Procalcitonin and Proadrenomedullin Concentrations as Predictive Markers for Early Onset Neonatal Sepsis. *Am J Biochem*. 2016;6(1):6–15.
 28. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20(3):629–37.
 29. Gracia S, Montañés R, Bover J, Cases A, Deulofeu R, De Francisco ALM, et al. Documento de consenso: Recomendaciones sobre la utilización de ecuaciones para la estimación del filtrado glomerular en adultos. *Nefrología*. 2006;26(6):658–65.
 30. BRAHMS MR-proADM KRYPTOR. Instruction for Use (version R10en). 18–1–2010. [Internet]. Thermo Fisher; 2010. Available from:

- <https://www.mrproadm.com/>
31. Miguel D, Prieto B, Costa M, Coto D, Alvarez F V. Cord blood plasma reference intervals for potential sepsis markers: Pro-adrenomedullin, pro-endothelin, and pro-atrial natriuretic peptide. *Clin Biochem* [Internet]. 2011;44(4):337–41. Available from: <http://dx.doi.org/10.1016/j.clinbiochem.2010.12.012>
 32. Admaty D, Benzing J, Burkhardt T, Lapaire O, Hegi L, Szinnai G, et al. Plasma midregional proadrenomedullin in newborn infants: Impact of prematurity and perinatal infection. *Pediatr Res*. 2012;72(1):70–6.
 33. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR®. *Clin Biochem* [Internet]. 2009;42(7–8):725–8. Available from: <http://dx.doi.org/10.1016/j.clinbiochem.2009.01.002>
 34. Kalman S, Buyan N, Yürekli M, Özkaya O, Bakkaloğlu S, Söylemezoğlu O. Plasma and urinary adrenomedullin levels in children with acute pyelonephritis. *Nephrology*. 2005;10(5):487–90.
 35. Dötsch J, Hänze J, Knüfer V, Steiß JO, Dittrich K, Seidel A, et al. Increased urinary adrenomedullin excretion in children with urinary-tract infection. *Nephrol Dial Transplant*. 1998;13(7):1686–9.
 36. Mak RH, Kuo HJ. Pathogenesis of urinary tract infection: An update. *Curr Opin Pediatr*. 2006;18(2):148–52.
 37. Kalman S, Buyan N, Yürekli M, Özkaya O, Bakkaloğlu S, Söylemezoğlu O. Plasma and urinary adrenomedullin levels in children with renal parenchymal scar and vesicoureteral reflux. *Pediatr Nephrol*. 2005;20(8):1111–5.
 38. Suzuki Y, Itoh H, Katagiri F, Sato F, Kawasaki K, Sato Y, et al. Relationship between plasma mid-regional pro-adrenomedullin level and resistance to antihypertensive therapy in stable kidney transplant recipients. *Peptides* [Internet]. 2013;48:45–8. Available from: <http://dx.doi.org/10.1016/j.peptides.2013.08.001>

Figures



CPR AUC = 0.81 (IC 95% 0.70 – 0.91)


PCT AUC = 0.74 (IC 95% 0.55 – 0.86)

P-MR-ProADM AUC = 0,41 (IC 95% 0,28 – 0,55)

U-MR-ProADM AUC = 0,67 (IC 95% 0,51 – 0,79)

Figure 1

ROC curve comparison of different biomarkers in patients with acute pyelonephritis (n=35/60).



CPR AUC = 0.87 (CI 95% 0.70 – 0.96)

PCT AUC = 0.92 (CI 95% 0.70 – 1)

P-MR-ProADM AUC = 0.92 (CI 95% 0.77 – 0.99)

U-MR-ProADM AUC = 0.75 (CI 95% 0,53 – 0.90)

Figure 2

ROC curve comparison of different biomarkers in patients with renal scars (7/35).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table1.pdf](#)
- [Table2.pdf](#)